메뉴 건너뛰기
Expert Opinion on Investigational Drugs
Volumn 19, Issue 2, 2010, Pages 311-314
Combining low-dose cyclophosphamide with GM-CSFsecreting prostate cancer immunotherapy enhances antitumor immune effects
Author keywords

Antitumor immunity; Cyclophosphamide; GVAX ; Immunotherapy; Prostate cancer
Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE;
EID: 74549124884     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903530678     Document Type: Note
Times cited : (14)
References (10)
  • 1
    • 33748162994 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer
    • Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24:419-424
    • (2006) Urol Oncol , vol.24 , pp. 419-424
    • Simons, J.W.1    Sacks, N.2
  • 2
    • 66249095192 scopus 로고    scopus 로고
    • Cyclophosphamide augments antitumor immunity: Studies in an autochthonous prostate cancer model
    • Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009;69:4309-4318
    • (2009) Cancer Res , vol.69 , pp. 4309-4318
    • Wada, S.1    Yoshimura, K.2    Hipkiss, E.L.3
  • 3
    • 21144454780 scopus 로고    scopus 로고
    • Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
    • Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J Exp Med 2005;201:1591-1602
    • (2005) J Exp Med , vol.201 , pp. 1591-1602
    • Ercolini, A.M.1    Ladle, B.H.2    Manning, E.A.3
  • 4
    • 0035328683 scopus 로고    scopus 로고
    • Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
    • Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-3697
    • (2001) Cancer Res , vol.61 , pp. 3689-3697
    • MacHiels, J.P.1    Reilly, R.T.2    Emens, L.A.3
  • 5
    • 12144287913 scopus 로고    scopus 로고
    • A phase i vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin
    • Emens LA, Armstrong D, Biedrzycki B, et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 2004;15:313-337
    • (2004) Hum Gene Ther , vol.15 , pp. 313-337
    • Emens, L.A.1    Armstrong, D.2    Biedrzycki, B.3
  • 6
    • 73349084990 scopus 로고    scopus 로고
    • Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine
    • Emens LA, Asquith JM, Leatherman JM, et al. Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine. J Clin Oncol 2009;27:5911-5918
    • (2009) J Clin Oncol , vol.27 , pp. 5911-5918
    • Emens, L.A.1    Asquith, J.M.2    Leatherman, J.M.3
  • 7
    • 40949157885 scopus 로고    scopus 로고
    • Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
    • Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-1463
    • (2008) Clin Cancer Res , vol.14 , pp. 1455-1463
    • Laheru, D.1    Lutz, E.2    Burke, J.3
  • 8
    • 71249156207 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer
    • Orlando, FL, USA, 26-28 Feb abstract LBA150
    • Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp, Orlando, FL, USA, 26-28 Feb 2009; abstract LBA150
    • (2009) Genitourin Cancer Symp
    • Higano, C.1    Saad, F.2    Somer, B.3
  • 9
    • 70349926513 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer
    • Orlando, FL, USA, 26-28 Feb abstract 7
    • Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp, Orlando, FL, USA, 26-28 Feb 2009; abstract 7
    • (2009) Genitourin Cancer Symp
    • Small, E.1    Demkow, T.2    Gerritsen, W.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.